CL2011003278A1 - Método para replegar una proteína expresada en un sistema de expresión no mamífero y presente en un volumen a una concentración de 2 g/l o mayor, que comprende poner en contacto la proteína con una solución amortiguadora al menos 2 mm que comprende un componente de óxidoreducción, desnaturalizante, antiagregante y estabilizador. - Google Patents

Método para replegar una proteína expresada en un sistema de expresión no mamífero y presente en un volumen a una concentración de 2 g/l o mayor, que comprende poner en contacto la proteína con una solución amortiguadora al menos 2 mm que comprende un componente de óxidoreducción, desnaturalizante, antiagregante y estabilizador.

Info

Publication number
CL2011003278A1
CL2011003278A1 CL2011003278A CL2011003278A CL2011003278A1 CL 2011003278 A1 CL2011003278 A1 CL 2011003278A1 CL 2011003278 A CL2011003278 A CL 2011003278A CL 2011003278 A CL2011003278 A CL 2011003278A CL 2011003278 A1 CL2011003278 A1 CL 2011003278A1
Authority
CL
Chile
Prior art keywords
protein
refolding
denaturing
stabilizer
concentration
Prior art date
Application number
CL2011003278A
Other languages
English (en)
Spanish (es)
Inventor
Joseph Edward Shultz
Roger Hart
Iii Ronald Nixon Keener
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42710673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011003278(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2011003278A1 publication Critical patent/CL2011003278A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CL2011003278A 2009-06-22 2011-12-22 Método para replegar una proteína expresada en un sistema de expresión no mamífero y presente en un volumen a una concentración de 2 g/l o mayor, que comprende poner en contacto la proteína con una solución amortiguadora al menos 2 mm que comprende un componente de óxidoreducción, desnaturalizante, antiagregante y estabilizador. CL2011003278A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21925709P 2009-06-22 2009-06-22

Publications (1)

Publication Number Publication Date
CL2011003278A1 true CL2011003278A1 (es) 2012-11-09

Family

ID=42710673

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011003278A CL2011003278A1 (es) 2009-06-22 2011-12-22 Método para replegar una proteína expresada en un sistema de expresión no mamífero y presente en un volumen a una concentración de 2 g/l o mayor, que comprende poner en contacto la proteína con una solución amortiguadora al menos 2 mm que comprende un componente de óxidoreducción, desnaturalizante, antiagregante y estabilizador.

Country Status (15)

Country Link
US (5) US8952138B2 (https=)
EP (2) EP3366692A1 (https=)
JP (2) JP5808323B2 (https=)
KR (1) KR101741859B1 (https=)
CN (1) CN102482321B (https=)
AU (1) AU2010270986B2 (https=)
BR (1) BRPI1011940B8 (https=)
CA (1) CA2765881C (https=)
CL (1) CL2011003278A1 (https=)
EA (1) EA020621B1 (https=)
IL (1) IL216954A (https=)
MX (1) MX2011013898A (https=)
SG (1) SG176963A1 (https=)
WO (1) WO2011005488A1 (https=)
ZA (1) ZA201200512B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020621B1 (ru) 2009-06-22 2014-12-30 Амген Инк. Рефолдинг белков с использованием химически контролируемого окислительно-восстановительного состояния
LT3660032T (lt) 2009-06-25 2026-02-25 Amgen Inc. Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2014128726A2 (en) * 2013-02-22 2014-08-28 Biogenomics Limited Process for high efficiency refolding of recombinant proteins
WO2017019776A1 (en) * 2015-07-27 2017-02-02 Purdue Research Foundation Tandem folding methods to improve protein folding yield
US10745457B2 (en) 2015-09-02 2020-08-18 Merck Sharp & Dohme Corp. Process for obtaining insulin with correctly formed disulfide bonds
CA3218290A1 (en) * 2016-07-22 2018-01-25 Amgen Inc. Methods of purifying fc-containing proteins
CN108276470A (zh) * 2017-01-06 2018-07-13 深圳市新产业生物医学工程股份有限公司 细胞裂解液、提取胞内蛋白的方法、制备弓形虫抗原的方法和试剂盒
WO2018190301A1 (ja) * 2017-04-10 2018-10-18 花王株式会社 角栓を除去する方法
CN111902720B (zh) 2018-03-21 2025-02-07 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
KR20210110294A (ko) * 2018-11-07 2021-09-07 어플라이드 몰레큘라 트랜스포트 인크. 통과세포외배출용 전달 구조체 및 관련 방법
PL4263568T3 (pl) 2020-12-18 2025-11-24 Richter Gedeon Nyrt. Sposoby oczyszczania poddanego ponownemu fałdowaniu białka fuzyjnego peptydu Fc
CN115894604B (zh) * 2022-12-16 2024-01-23 康日百奥生物科技(苏州)有限公司 重组蛋白澄清纯化方法

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468464A (en) 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
WO1984003711A1 (en) 1983-03-25 1984-09-27 Celltech Ltd A process for the production of a protein
US4468454A (en) 1983-06-10 1984-08-28 E. I. Du Pont De Nemours And Company Antifoggant process
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
GB8508340D0 (en) 1985-03-29 1985-05-09 Creighton T E Production of protein
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
CA1339757C (en) 1987-04-16 1998-03-17 Robert F. Halenbeck Production of purified biologically active, bacterially produced recombinant human csf-1
IL86090A (en) 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
CA1329119C (en) 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
GB8807673D0 (en) 1988-03-31 1988-05-05 Lingner & Fischer Gmbh Novel article
JP2796388B2 (ja) 1988-05-13 1998-09-10 アムジエン・インコーポレーテツド G−csfの精製方法
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5986070A (en) 1990-04-06 1999-11-16 Amgen Inc. Production of biologically active NGF proteins
AU664021B2 (en) 1990-09-05 1995-11-02 Natinco Nv Solubilization of proteins in active forms
WO1993018136A1 (en) 1992-03-05 1993-09-16 Cytomed, Inc. Process for supporting hematopoietic progenitor cells
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
EP0657466B1 (en) 1993-11-10 1997-01-15 Pfizer Inc. A process for refolding of (pro-)chymosin, comprising recycling of urea
US5466377A (en) 1994-01-19 1995-11-14 Grandics; Peter Chromatography media and their uses
IL113497A0 (en) 1994-04-28 1995-07-31 Amgen Inc Method for controlling metallophosphate precipitation in high cell density fermentations
AU2603995A (en) * 1994-05-25 1995-12-18 University Of Nebraska Board Of Regents Biologically active glycoprotein hormones produced in procaryotic cells
AU6028396A (en) 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
DE69733950T2 (de) 1996-01-23 2006-07-06 Ortho-Mcneil Pharmaceutical, Inc. Methode zur reinigung eines erythrpoietinbindenden proteins
US5935824A (en) 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US20020052026A1 (en) 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
US6180391B1 (en) 1998-01-28 2001-01-30 Amgen Inc. Highly efficient controlled expression of exogenous genes in e. coli
US6653098B1 (en) * 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP2003505471A (ja) 1999-07-21 2003-02-12 アムジエン・インコーポレーテツド Vgfポリペプチドおよびvgf関連障害の治療方法
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
DE60138715D1 (de) 2000-09-05 2009-06-25 Amgen Inc Tnf-rezeptor-ähnliche moleküle und deren anwendungen
JP2005505494A (ja) 2001-02-23 2005-02-24 イミュネックス・コーポレーション 活性タンパク質の回収増加
US6972327B1 (en) 2001-05-08 2005-12-06 Immunex Corporation Regeneration of chromatography material
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
ITMI20012345A1 (it) 2001-11-08 2003-05-08 Internat Ct For Genetic En Gin Procedimento per la produzione di interferone alfa di grado terapeutico
SI21102A (sl) 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
AU2002345829A1 (en) 2002-06-24 2004-01-06 Dr. Reddy's Laboratories Ltd. Process for preparing g-csf
US7067279B1 (en) 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
CN101287484B (zh) 2002-12-20 2012-10-10 安姆根有限公司 抑制肌肉生长抑制素的结合剂
US7083948B1 (en) 2002-12-24 2006-08-01 Immunex Corporation Polypeptide purification reagents and methods for their use
EP1449848A1 (en) 2003-02-20 2004-08-25 GBF German Research Centre for Biotechnology Method for the production of cystine-knot proteins
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
DE602004026343D1 (de) 2003-10-24 2010-05-12 Amgen Inc Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen
US7781395B2 (en) 2004-01-30 2010-08-24 Immunex Corporation Process for purifying proteins
WO2005089102A2 (en) 2004-02-04 2005-09-29 Neose Technologies, Inc. Methods of refolding mammalian glycosyltransferases
WO2005092914A1 (en) 2004-03-22 2005-10-06 Blue Mountain Technology Development Lab Process for promoting proper folding of human serum albumin using a human serum albumin ligand
FR2874318B1 (fr) 2004-08-19 2006-11-24 Oreal Utilisation en cosmetique de composes polysaccharidiques amphoteres a chaine(s) polymerique(s) cationique(s)
NZ553420A (en) 2004-08-19 2010-02-26 Biogen Idec Inc Refolding transforming growth factor beta family proteins
DE102004041639A1 (de) 2004-08-27 2006-03-02 Bioceuticals Arzneimittel Ag Verfahren zur Gewinnung von biologisch aktivem humanen G-CSF aus Inclusion Bodies
EA011879B1 (ru) 2004-09-24 2009-06-30 Эмджин Инк. МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
US7435804B2 (en) 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b
JP5553963B2 (ja) 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
DK1828239T3 (da) 2004-12-10 2011-12-19 Zymogenetics Inc FGF18-produktion i prokaryote værter
CA2594502A1 (en) 2005-01-28 2006-08-03 Zymogenetics Inc. Homogeneous preparations of il-31
WO2006097944A2 (en) 2005-03-17 2006-09-21 Zenotech Laboratories Limited Process for the purification of recombinant granulocyte-colony stimulating factor
US7344962B2 (en) 2005-06-21 2008-03-18 International Business Machines Corporation Method of manufacturing dual orientation wafers
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7735525B2 (en) 2005-11-14 2010-06-15 Amgen Inc. Thermally insulated apparatus for liquid chromatographic analysis
WO2007075283A2 (en) 2005-12-06 2007-07-05 Amgen Inc. Polishing steps used in multi-step protein purification processes
NZ568809A (en) 2005-12-22 2011-08-26 Genentech Inc Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents
US7612273B2 (en) * 2006-03-20 2009-11-03 Roland Corporation Electronic percussion instrument
EP1845103B1 (en) * 2006-04-10 2015-02-25 Boehringer Ingelheim RCV GmbH & Co KG Method for refolding a protein
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス, インコーポレイテッド Il−17およびil−23アンタゴニストならびにその使用方法
US20080125580A1 (en) 2006-07-14 2008-05-29 Genentech, Inc. Refolding of Recombinant Proteins
EP2049821A4 (en) 2006-07-21 2013-09-04 Amgen Inc Rupture valve
WO2008097829A2 (en) 2007-02-02 2008-08-14 Neose Technologies, Inc. Large scale production of eukaryotic n-acetylglucosaminyltransferase i in bacteria
TW201307390A (zh) 2007-02-02 2013-02-16 Amgen Inc 海帕西啶(hepcidin)、海帕西啶拮抗劑及使用方法
WO2008096370A2 (en) 2007-02-05 2008-08-14 Natco Pharma Limited An efficient and novel purification method of recombinant hg-csf
WO2008100578A2 (en) 2007-02-14 2008-08-21 Amgen Inc. Method of isolating antibodies by precipitation
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
US20110003337A1 (en) 2008-02-29 2011-01-06 Ramot At Tel-Aviv University Ltd. Immunoglobulin compositions and methods of producing same
LT3216803T (lt) 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
EA020621B1 (ru) 2009-06-22 2014-12-30 Амген Инк. Рефолдинг белков с использованием химически контролируемого окислительно-восстановительного состояния
LT3660032T (lt) * 2009-06-25 2026-02-25 Amgen Inc. Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
TWI648532B (zh) 2011-08-29 2019-01-21 美商安美基公司 用於非破壞性檢測-流體中未溶解粒子之方法及裝置
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US20160038588A1 (en) 2013-03-15 2016-02-11 Amgen Inc. Myostatin Antagonism in Human Subjects
US9632095B2 (en) 2014-12-01 2017-04-25 University Of Delaware Device and method for determining reaction kinetics
US9704239B1 (en) 2016-09-02 2017-07-11 Amgen Inc. Video trigger synchronization for improved particle detection in a vessel

Also Published As

Publication number Publication date
US12269843B2 (en) 2025-04-08
EP2445923A1 (en) 2012-05-02
EA201270015A1 (ru) 2012-05-30
AU2010270986B2 (en) 2014-05-22
IL216954A0 (en) 2012-02-29
US20170145049A1 (en) 2017-05-25
JP6026608B2 (ja) 2016-11-16
EP3366692A1 (en) 2018-08-29
SG176963A1 (en) 2012-02-28
EP2445923B1 (en) 2018-09-05
CN102482321A (zh) 2012-05-30
JP2016028065A (ja) 2016-02-25
CA2765881A1 (en) 2011-01-13
MX2011013898A (es) 2012-05-22
US20150315232A1 (en) 2015-11-05
AU2010270986A1 (en) 2012-01-19
IL216954A (en) 2016-09-29
CN102482321B (zh) 2015-06-17
WO2011005488A1 (en) 2011-01-13
BRPI1011940A2 (pt) 2016-11-22
US8952138B2 (en) 2015-02-10
JP5808323B2 (ja) 2015-11-10
KR101741859B1 (ko) 2017-06-15
KR20120052939A (ko) 2012-05-24
US9856287B2 (en) 2018-01-02
US20150329586A1 (en) 2015-11-19
JP2012530782A (ja) 2012-12-06
EA020621B1 (ru) 2014-12-30
BRPI1011940B1 (pt) 2021-07-20
US20190055281A1 (en) 2019-02-21
US20100324269A1 (en) 2010-12-23
ZA201200512B (en) 2012-11-28
CA2765881C (en) 2016-08-02
BRPI1011940B8 (pt) 2021-08-03

Similar Documents

Publication Publication Date Title
CL2011003278A1 (es) Método para replegar una proteína expresada en un sistema de expresión no mamífero y presente en un volumen a una concentración de 2 g/l o mayor, que comprende poner en contacto la proteína con una solución amortiguadora al menos 2 mm que comprende un componente de óxidoreducción, desnaturalizante, antiagregante y estabilizador.
BRPI0909201A2 (pt) Dispositivo e processo de balanceamento de pressão em pelo menos um alojamento de mancal de turborreator, e, turborreator.
ECSP088758A (es) Métodos para reducir la aglomeración de proteína
WO2007067743A3 (en) Optical determination of glucose utilizing boronic acid adducts-ii
BRPI1008681A2 (pt) monitor com iluminação traseira com adaptação de àrea e método com computação e características de auréola reduzidas.
BR112012013362A2 (pt) sistema para a determinação de um valor para pelo menos um parâmetro que descreve a atividade microbiana de organismos biológicos individuais em uma amostra de líquido, e, método para a determinação da atividade microbiana em uma amostra de líquido
BRPI0919034A8 (pt) Métodos para produzir uma proteína e um anticorpo, meio líquido aquoso para cultura, e, vaso
ATE542903T1 (de) Luciferase-biosensoren für camp
CO6470854A2 (es) Variantes de celulasa con expresión, actividad y/o estabilidad mejoradas, y uso de las mismas
BRPI0906549A2 (pt) Bandagens médicas com válvulas e kits contendo as mesmas.
BRPI0912751A2 (pt) métodos de análise e avaliação de um objeto com um sistema de laser de ultra som e instrumento para inspecionar um objeto.
BRPI0914455A2 (pt) "processo para medir a concentração microbiológica total em um meio aquoso, método para medir o conteúdo de biofilme em um meio aquoso e sistema para medir concentração microbiológica total em um meio aquoso"
EP2286374A4 (en) SYSTEM AND METHOD FOR PROVIDING QUESTIONS AND ANSWERS WITH DELAYED ASSESSMENT
BRPI0923630A2 (pt) sistemas e métodos de processamento e incorporação de amostras de tecido para biópsia durante processo de histopalogia e de realização de pelo menos parte do mesmo.
EP2023941A4 (en) PROTEIN NETWORK, NETWORKING METHOD AND ITS APPLICATIONS
DE602009000214D1 (de) Gefühlerkennungsmitteilungssystem und Mitteilungsspeicherserver dafür
BRPI0922750A2 (pt) sensor de pressão, e, método para medir pressões em um processo industrial.
IT1397197B1 (it) Veicolo battipista e relativo metodo di controllo.
ITFI20060322A1 (it) Processo per la preparazione di elettrodi modificati, elettrodi preparati con tale processo, e biosensori enzimatici che li comprendono.
BR112014006405A2 (pt) anticorpo, conjunto, e, método para medir um complexo de afinidade
BRPI0906513A2 (pt) Látex de borracha natural com alergenicidade reduzida e método de fabricação.
MX2011004483A (es) Leucolectinas y sus usos.
BR112012014865A2 (pt) lentes de contato estabilizadas
WO2019139980A8 (en) Methods for measuring analyte and/or protein in biological samples
BRPI0912249A2 (pt) método de prevenir o desenvolvimento de artrite reumatoide em indivíduos com artrite não diferenciada.